Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
出版年份 2018 全文链接
标题
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
作者
关键词
Clinical research, Clinical trials, Multiple myeloma, Myeloma therapy
出版物
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-04-19
DOI
10.1186/s13045-018-0583-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) David S. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
- (2017) M A Dimopoulos et al. Blood Cancer Journal
- Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
- (2016) H. Avet-Loiseau et al. BLOOD
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
- (2016) Sundar Jagannath et al. Expert Review of Hematology
- Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
- (2016) Pellegrino Musto et al. Expert Review of Hematology
- Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study
- (2015) María Victoria Mateos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients
- (2015) C. Cerrato et al. Clinical Lymphoma Myeloma & Leukemia
- Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States
- (2015) Xue Song et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
- (2015) M. A. Dimopoulos et al. HAEMATOLOGICA
- Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Defining and treating high-risk multiple myeloma
- (2015) S Z Usmani et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
- (2015) M. A. Dimopoulos et al. HAEMATOLOGICA
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
- (2014) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance
- (2013) M. Varettoni et al. BLOOD
- Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
- (2013) R. Niesvizky et al. CLINICAL CANCER RESEARCH
- Association of response endpoints with survival outcomes in multiple myeloma
- (2013) S Lonial et al. LEUKEMIA
- The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment
- (2013) L. P. Garrison et al. ONCOLOGIST
- Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
- (2013) Robert Z. Orlowski SEMINARS IN ONCOLOGY
- Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study
- (2013) Karin Jordan et al. SUPPORTIVE CARE IN CANCER
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry
- (2012) Floortje Mols et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
- (2010) Asher A. Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study
- (2010) X. Armoiry et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
- (2010) H Avet-Loiseau et al. LEUKEMIA
- Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: A 5-year retrospective analysis
- (2008) Ola Ghatnekar et al. CLINICAL THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started